M. Alhadj Ali

INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes

E. Bonifacio, M. Knip, D. Dunger, 2022, Trials.

Phenotypic Analysis of Human Lymph Nodes in Subjects With New-Onset Type 1 Diabetes and Healthy Individuals by Flow Cytometry

D. Gerlag, T. Tree, Jennie H M Yang, 2019, Front. Immunol..

Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes

F. Wong, Martina A. McAteer, J. Ludvigsson, 2022, Immunotherapy advances.

Stimulated urine C‐peptide creatinine ratio vs serum C‐peptide level for monitoring of β‐cell function in the first year after diagnosis of Type 1 diabetes

M. Peakman, G. Dunseath, Y. Liu, 2016, Diabetic medicine : a journal of the British Diabetic Association.

Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes

C. Beam, F. Wong, R. Hills, 2017, Science Translational Medicine.

Topical steroid therapy induces pro-tolerogenic changes in Langerhans cells in human skin

F. Wong, J. Birchall, S. Coulman, 2015, Immunology.

Gene expression signature predicts rate of type 1 diabetes progression

Maria K. Jaakkola, E. Bonifacio, C. de Beaufort, 2023, EBioMedicine.

Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes

C. Beam, F. Wong, R. Hills, 2017, Science Translational Medicine.